JPH0428245B2 - - Google Patents
Info
- Publication number
- JPH0428245B2 JPH0428245B2 JP60226665A JP22666585A JPH0428245B2 JP H0428245 B2 JPH0428245 B2 JP H0428245B2 JP 60226665 A JP60226665 A JP 60226665A JP 22666585 A JP22666585 A JP 22666585A JP H0428245 B2 JPH0428245 B2 JP H0428245B2
- Authority
- JP
- Japan
- Prior art keywords
- piroxicam
- inflammatory
- composition
- pharmaceutically suitable
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960002702 piroxicam Drugs 0.000 claims description 70
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 46
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 43
- 229960005489 paracetamol Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 16
- 229960005426 doxepin Drugs 0.000 claims description 14
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 14
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 12
- 229960005414 pirbuterol Drugs 0.000 claims description 12
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 10
- 229960003529 diazepam Drugs 0.000 claims description 10
- 235000008160 pyridoxine Nutrition 0.000 claims description 8
- 239000011677 pyridoxine Substances 0.000 claims description 8
- 229940011671 vitamin b6 Drugs 0.000 claims description 8
- 230000000767 anti-ulcer Effects 0.000 claims description 7
- 239000002085 irritant Substances 0.000 claims description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000002587 enol group Chemical group 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 241000700159 Rattus Species 0.000 description 18
- 239000002775 capsule Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 14
- 208000025865 Ulcer Diseases 0.000 description 13
- 230000002496 gastric effect Effects 0.000 description 13
- 230000006378 damage Effects 0.000 description 11
- 239000007903 gelatin capsule Substances 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000012458 free base Substances 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960000905 indomethacin Drugs 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- 208000007107 Stomach Ulcer Diseases 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 229940099112 cornstarch Drugs 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- FVTSYHPRVGNAQI-UHFFFAOYSA-N 2-aminoethanol;4-hydroxy-2-methyl-1,1-dioxo-n-pyridin-2-yl-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound NCCO.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 FVTSYHPRVGNAQI-UHFFFAOYSA-N 0.000 description 5
- 150000002169 ethanolamines Chemical class 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 229920003109 sodium starch glycolate Polymers 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 3
- 206010053155 Epigastric discomfort Diseases 0.000 description 3
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960002861 doxepin hydrochloride Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- -1 pyridoxine Natural products 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- QSXMZJGGEWYVCN-UHFFFAOYSA-N Pirbuterol acetate Chemical compound CC(O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 QSXMZJGGEWYVCN-UHFFFAOYSA-N 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- IHTYTYHXCRAMAV-UHFFFAOYSA-N acetic acid;dihydrochloride Chemical group Cl.Cl.CC(O)=O IHTYTYHXCRAMAV-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 231100000673 doseâresponse relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004994 pirbuterol acetate Drugs 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
ç£æ¥äžã®å©çšåé
æ¬çºæã¯æãã€å€ããã»ãã³ãšæççå€ããã
ã·ã«ã ãŸãã¯ãã®å»è¬ãšããŠé©åœãªå¡©ãçµåãã
çµæç©ã«é¢ãããæ¬æ现æžã«äœ¿çšãããå±åã¯ã°
ãªãã€ã¹ãïŒGriffithsïŒç·šéã®ãžUSANã¢ã³ã
ãžUSPãã€ã¯ã·ãšããªãŒãªããã©ãã°ãã€ã ã¹
ïŒthe USAN and the USP Dictonary of Drug
NamesïŒã1961ã1981ãU.S.Pharmacopeial
Convention Inc.RockvilleãMdã1984ããçšã
å ¬åŒã®USANåãšåž°å±ããŠäº€ä»ãããããŸãã¯
ã¶ã¡ã«ã¯ã€ã³ããã¯ã¹10ã¹ãšãã€ã·ãšã³ïŒthe
Merck Index 10th EditionïŒã«è¡šããããŠããã æççå€ã«ã¯äžè¬ã«ä»éããå¯äœçšãšããŠæœ°ç
ãå«ããèè žåºæ¿ãå€å°ã¯çãããå€ãã®å Žåã
ãã®ãããªæççæ²»çãå¿ èŠãšããåºäœã¯ããã®
ãããªå¯äœçšãžã®æåæ§ã®ãããã®å©çã®äº«åã
劚ããããŠãããäžã§å®çŸ©ãããå»è¬åãšããã
ã·ã«ã ãšã®æ¬çµåãã¯äžè¿°ã®èè žåºæ¿ãŸãã¯æœ°ç
ãé²æ¢ãããæ¹åããç®çã®æççæ²»çãå¯èœã«
ããã åŸæ¥ã®æè¡ ã¢ã»ãã¢ããããšã³ã¯ã¢ã¹ããªã³ã®æœ°çèªçºæ§
ãæžå°ããããã·ãŠã¬ãŒã¹ïŒSugersïŒãããžã€
ãŒãã«ãªããã¢ãŒãã·ãŒã¢ã³ããã¢ãŒãã³ããžãŒ
ïŒJ.Pharm.Phaymacol.ïŒ30ã84ïŒ1978ïŒïŒåæžã
31ã840ïŒ1979ïŒïŒããã³ã¢ããã³ã»ã¹ãªãããã¹
ã¿ã°ã©ã³ãžã³ã¢ã³ãã¹ãã³ãããµã³ãªãµãŒã
ïŒAdv.Prost.Thromb.Res.ïŒïŒã1547ïŒ1980ïŒããŸ
ãã¯é žæ§åã¢ã¹ããªã³ã®æœ°çèªçºæ§ãæžå°ããã
ãã³ã³ãã¬ãã¯ïŒKonturekïŒããã¬ããïŒGutïŒã
23ã536ïŒ1982ïŒããšä»¥åã«å ±åãããŠããããã
ããã€ã³ãã¡ã¿ã·ã³ã¯é žæ§åã¢ã¹ããªã³ãæäžã
ãæã«ã¯ã¢ã»ãã¢ããããšã³ã®ä¿è·äœçšãé転ã
ããïŒäžèšåŒçšæïŒãæè¿ã®ç 究ã§ã¯ãã¢ã»ãã¢
ããããšã³ã¯ã€ã³ãã¡ã¿ã·ã³ããã³ã¢ã¹ããªã³ã®
朰çèªçºæ§ãæžå°ãããããšãã«ãã¿ãŸã³ãŸãã¯
ã°ã©ããšãã³ããã³æé«æäžïŒ800mgïŒKgïŒæã®
ã€ãããããšã³ã®æœ°çèªçºæ§ã¯æžå°ãããªããšå ±
åãããããã¢ã³ã³ã«ãã·ãšãã³ïŒvan
KolfschotenïŒãããšã€ãžãšã³ãã¢ã¯ã·ãšã³ãº
ïŒAgents ActionsïŒ12ã247ïŒ1982ïŒïŒããã·ã³ã
ãžãŒã¢ã³ãã¢ãã©ã€ããã¢ãŒãã³ããžãŒ
ïŒToxicology Applied Pharm.ïŒ69ã37ïŒ1983ïŒãã
ã±ãããããšã³ããã³ä»ã®ç¹å®ã®æççå€ãšçµå
ããã¢ã»ãã¢ããããšã³ã¯åäžæ·»å æã®å¹æãã
ã倧ããªé®çå¹æãäŸçµŠãããšå ±åãããïŒç±³åœ
ç¹èš±ç¬¬4233313ã4233317å·ïŒ4234601å·ïŒ4207340
å·ããã³4242353å·ïŒããããã·ã«ã ãŸãã¯ä»ã®ã
ããªããªãã·ã«ã ãšã¢ã»ãã¢ããããšã³ãšã®äœµçš
ã«é¢ããŠã¯ããããªãç®ççšã«ã以åã«å ±åãã
ãŠã¯ããªãã æ°ç®¡æ¯æ¡åŒµå€ãµã«ãã¿ã¢ãŒã«ïŒã¢ã«ããããŒ
ã«ïŒããšãã«ãšããšããªã³ããã³ã€ãœãããã¬ã
ãŒã«ã¯åç©ã«ãããã€ã³ãã¡ã¿ã·ã³èªçºæ§æœ°çã®
圢æãæå¶ããããããã©ãããŒã«ã¯æå¶ããªã
ãšå ±åãããŠããããã€ãŒã«ãã€ã³ã°
ïŒFieldingïŒãããšãŒããã¢ã³ãµãŒãžã«ã«ãªãµãŒ
ãïŒEur Surg ResïŒïŒã252ïŒ1977ïŒïŒã«ã¹ã€
ïŒKasuyaïŒãããžã€ãããŒãºãžã€ãŒãã«ãªããã¢
ãŒãã³ããžãŒJapan J.Pharm.ïŒ29ã670ïŒ1979ïŒãã
ä»ã®ç 究ã§ã¯ãç¬ã®åºåºå®€éšäœãžã®ã€ãœãããã¬
ããŒã«æäžã¯ã¢ã¹ããªã³èªçºæ§çµç¹æå·ã軜æžãŸ
ãã¯é²æ¢ããããããã¯ã°ãªãŒããŒïŒMcGreevyïŒ
ãããµãŒãžã«ã«ããªãŒã©ã ïŒSurg.ForumïŒ28ã
357ïŒ1977ïŒããæ°ç®¡æ¯æ¡åŒµå€ãã«ããããŒã«ã®æç
çå€ãžã®åœ±é¿ã«é¢ããå ±åã¯ãŸã ç¥ãããŠããª
ãã æãã€å€ããã»ãã³ãèã®åæ³æå¶æŽ»æ§ããæ
ãã人éã®åäºæè žæœ°çæ²»çã«ãããŠã·ã¡ããžã³
ãšåæ§ã«æå¹ã§ãããšå ±åãããŠãããããã
ïŒHoffïŒããã«ã¬ã³ãã¡ãã€ã«ã«ãªãµãŒãã¢ã³ã
ãªãããªã³ïŒCurr Med Res OpinïŒç¬¬ïŒå·»ãå¢
åïŒã36ããŒãžïŒ1980ïŒïŒã¹ã«ã³ãžããã¢ã³ãžã€
ãŒãã«ãªãã¬ã¹ãããšã³ããããžãŒïŒScand.J.
Gastroent.ïŒã16ã1041ïŒ1981ïŒããããã»ãã³ãã©
ããããã³ç¬ã«ãããŠæœ°çæå¶ããã³åæ³æå¶æŽ»
æ§ã瀺ãã氎浞ææã«ããã¹ãã¬ã¹ããããã©ã
ãã«ãããŠã€ã³ãã¡ã¿ã·ã³ããžã¯ãããšããã¯ã
ãã³ã¢ã¹ããªã³ã®æœ°çèªçºåãèããæžå°ããã
ããšãå ±åãããŠãããã¬ã€ããŒã«ãïŒLeitoldïŒ
ããã¢ãŒã«ã€ãã¹ãªããã¢ãŒãã³ããžãŒïŒArch.
Pharmacol.ïŒ316ïŒå¢åïŒãR50ãèŠçŽ199
ïŒ1981ïŒïŒã¬ã€ããŒã«ãïŒLeitoldïŒããã¢ããã³
ã»ã¹ã€ã³ãšã¯ã¹ããªã¡ã³ã¿ã«ãŠã«ãµãŒ
ïŒAdvances in Experimental UlcerïŒããŠãšãã©
ããã³ã€ããŠç·šéãICEU.Tokyo.pp27ã36
ïŒ1982ïŒïŒã¢ã«ããã€ãããã«âããªã«ã·ãŠã³ã°ïŒ
ãã©ãã¯ãªãµãŒãïŒArzneim.âForsch.ïŒDrug
Res.ïŒã34ã468ïŒ1984ïŒãã ã¡ãžã€ãŒãã©ã³ãã©ã€ã¶ãŒã§æ粟ç¥ç å€ã§ãã
ã¯ãã«ããããžã³ã¯ã©ããã®ã€ã³ãã¡ã¿ã·ã³èªçº
æ§è朰çã軜æžãããšå ±åãããŠãããã«ã¹ã€
ïŒKasuyaïŒããäžèšåŒçšæïŒ1979ïŒããæè¿ãå ç«
調æŽå€ã¬ãããœãŒã«ãã©ããã®ãããã·ã«ã ãã
ã³ã€ã³ãã¡ã¿ã·ã³èªçºæ§æœ°çã®äž¡è ãšã軜æžãã
ãšå ±åãããŠããããšãã³ã²ãªã¹ã¿
ïŒEvangelistaïŒãããžã€ãŒãã«ãªããã¢ãŒãã·ãŒ
ã¢ã³ããã¢ãŒãã³ããžãŒïŒJ.Pharm.Pharmacol.ïŒ
36ã270ïŒ1984ïŒããããããéã¹ããã€ãç³»æçç
å€ã«ããèªçºãããèãžã®å¯äœçšã®è»œæžã«ããªã
ãŸã·ã³ã®ãããªæé«è¡å§å€ãããªããã·ã³ã®ãã
ãªãã¿ãã³ãŸãã¯ãžã¢ãŒãã ã®ãããªãã€ããŒã
ã©ã³ãã©ã€ã¶ãŒã®äœ¿çšã«é¢ããå ±åã¯ããŸã ã«ç¥
ãããŠããªãã ãªã³è質ãéã¹ããã€ãç³»æççå€ãç¹ã«ã€ã
ããããšã³ãããããã»ã³ããžã¯ãããšããã¯ã
ãã³ãã«ãªãããããšã³ã®ããšãã«é ¢é žããã³ã
ãšãã«ããããªã³é žèªå°äœãã®ã¯ãžãŒïŒGkyczyïŒ
ããç±³åœç¹èš±ç¬¬4369182å·ïŒ1983ïŒãã以åã€ã³ã
ã¡ã¿ã·ã³ããã³ä»ã®æççå€ãšäœµçšããã朰çæ
å¶å€ãã¬ã³ãŒãã³ãã¬ã€ããŒã«ãïŒLeitoldïŒãã
ãã©ãã€ããã·ãšïŒTherapiewocheïŒã27ã
pp1532ã1548ïŒ1977ïŒïŒãã€ãç¹èš±ç¬¬2708520å·ã
ããã³ã©ãããžã³ãã·ã¡ããžã³ããã³ïŒâã¡ãã«
âïŒâããïŒâïŒïŒâãããªãžãã«ã¡ãã«ïŒããšã
ãã·ãâãããã«ã¢ããããâ1HâïŒïŒïŒïŒïŒâã
ãªã¢ãŸãŒã«âïŒâã¡ã¿ããŒã«ã®ãããªãã¹ããžã³
âH2æ®ææ§ïŒèé žåæ³æå¶ã朰çæå¶ïŒååç©ã
ãšäœµçšããå Žåã«èè žã®èŠçïŒç²èãžã®æå·ãè
朰ç圢æïŒã軜æžãããšå ±åãããŠãããäŸã
ã°ãè±åœç¹èš±ç¬¬2105193ããã³2105588å·ïŒããã³
ã©ãã¬ã€ã¹ïŒLavelaceïŒãç±³åœç¹èš±ç¬¬4230717å·
ãåç §ããã ãã³ãã«ãžãïŒLombardinoïŒã«ããåæåºé¡
ãããç±³åœç¹èš±ç¬¬4567179å·ã¯ããªããŸã·ã³ãã
ãã»ãã³ãâãžã¡ãã«ããã»ãã³ãããªããã·
ã³ãã€ãœãããã¬ããŒã«ããã³ãã«ããããŒã«ã
å«ãããããã·ã«ã ã®æ¹è¯ãããæççæ§å¡©ã«ã€
ããŠèšè¿°ããŠããã çºæã解決ããããšããåé¡ç¹ æ¬çºæã¯æççéã®ãããã·ã«ã ãŸãã¯ãã®å»
è¬ãšããŠé©åœãªå¡©ïŒç¹ã«ãšã¿ããŒã«ã¢ãã³å¡©ïŒã
ãããã·ã«ã èªçºæ§èåºæ¿éããã³æœ°çæå¶éã®
ã¢ã»ãã¢ããããšã³ãããã»ãã³ããã«ããããŒ
ã«ããžã¢ãŒãã ãããªããŸã·ã³é¡ãããªããã·ã³
é¡ããã³ãããã®å»è¬ãšããŠé©åœãªå¡©ãšäœµçšãã
ããšãç¹é·ãšããæçççµæç©ã®æ¹è¯ã«é¢ããã åé¡ã解決ããããã®æ段 æ¬çºæã®æççããããã·ã«ã ã¯æ¢ç¥ç©è³ªã§ã
ããäŸãã°ãã¶ã¡ã«ã¯ã€ã³ããã¯ã¹ïŒthe Merck
IndexïŒç¬¬10çã1983ã«ã¯ãããã·ã«ã ã«é¢ãã
éçŽïŒNo.7378ïŒãå«ãŸããŠãããã¶ãã€ãžã·ã¢ã³
ãºãã¹ã¯ãªãã¢ã¬ã³ã¹ãThe Physicians Desk
ReferenceïŒPDRïŒãã«ãå«ãŸããŠããã奜é©ãªã
ããã·ã«ã ã®ãšã¿ããŒã«ã¢ãã³å¡©ã¯ç±³åœç¹èš±ç¬¬
4434164å·ã«æ確ã«é瀺ãããŠããã æã ããããã·ã«ã èªçºæ§èåºæ¿ããã³æœ°çã
æå¶ããããšãèŠåºããæ¬çºæã®ååç©ãæ¢ç¥å
åç©ã§ãããã¢ã»ãã¢ããããšã³ã¯å°å£²ã®é®çå€
ãã¶ã¡ã«ã¯ã€ã³ããã¯ã¹ïŒthe Merck IndexïŒç¬¬
10çãéæçªå·39ïŒPDR第38çãp.2096ãåç §ã
ã§ãããããã»ãã³ã¯ãã®å¡©é žå¡©ã®åœ¢ç¶ã§è²©å£²ã
ããŠããæãã€å€ã§ãããã¶ã¡ã«ã¯ã€ã³ããã¯ã¹
ïŒthe Merck IndexïŒç¬¬10çãéçŽçªå·3434ïŒ
PDR第38çãpp.1688ã1689ïŒãããã«ããããŒã«
ã¯ãã®äºå¡©é žäžé ¢é žå¡©ã®åœ¢ç¶ã§äžçäžã«è²©å£²ãã
ãŠããæ°ç®¡æ¯æ¡åŒµå€ã§ãããã¶ã¡ã«ã¯ã€ã³ããã¯
ã¹ïŒthe Merck IndexïŒç¬¬10çãéçŽçªå·7364
ãåç §ãããæ°ç®¡æ¯æ¡åŒµå€ãšããŠã®åæã®åæã
ãã³å¹çšã¯ç±³åœç¹èš±ç¬¬3700681ïŒ3763173ïŒ
3772314ããã³3786160å·ã«é瀺ãããŠãããã»ã
ã«äžè¬çã«æ¹è¯ãããåæãç±³åœç¹èš±3948919ïŒ
4011231ïŒããã³4031108å·ïŒã«ã¯ã»ã³ãã«ã°ç¹èš±
第79564å·ããã³ãšãŒãããç¹èš±ç³è«ç¬¬58069ã
58070ã58071ããã³58072å·ã«ç€ºãããŠãããæŽ
ã«æè¿ããã«ããããŒã«ã¯æ¬è¡æ§å¿äžå šã®æ²»çã«
ãæå¹ã§ããããšãå€æããïŒç±³åœç¹èš±ç¬¬
4175128å·ïŒããžã¢ãŒãã ã¯åºãåŠæ¹ãããŠããã
ã€ããŒãã©ã³ãã©ã€ã¶ãŒã§ãããã¶ã¡ã«ã¯ã€ã³ã
ãã¯ïŒthe Merck IndexïŒç¬¬10çãéçŽçªå·
2967ïŒPDR第39çãpp.1671ã1674ããããªã¢ãŸ
ã·ã³ãã¶ã¡ã«ã¯ã€ã³ããã¯ã¹ïŒthe Merck
IndexïŒç¬¬10çãéçŽçªå·9506ïŒãã¯å¡©é žå¡©ãšã
ãŠäžçäžã«è²©å£²ãããŠããæ§é äžãã©ãŸã·ã³ã«é¢
é£ããæè¡å§å€ã§ãããããªããã·ã³ã¯B6è€å
äœã®ãã¿ãã³ã®äžã€ãšããŠå¡©é žå¡©ãšããŠè²©å£²ãã
ãŠããã ãããã·ã«ã èªçºæ§èåºæ¿ããã³æœ°çã®æå¶ã«
ãããæ¬çºæã®æ¹è¯åŠæ¹ã®èšåºç䟡å€ã¯é©åœãªå
ç©å®éšã«åæ ãããããããã·ã«ã èªçºæ§èå·å®³
ãé²æ¢ãŸãã¯è»œæžããããã®è©Šéšååç©ã®èœåã
決å®ãã代衚çãªå®éšèšé²ãäžèšã®å®æœäŸã«ç€º
ãã æ¬çºæã¯å®¹æã«å®æœã§ããããããã·ã«ã ãŸã
ã¯ãã®å¡©ãåç©ãç¹ã«äººéã«0.1ãïŒmgïŒKgïŒæ¥
ã®ç¯å²ã§æäžããã第äºã®å»è¬åãå¥ã ã«æäžã
ãå Žåã«ã¯ãå è¡æè¡ïŒäŸãã°äžèšã®åŒçšæç®ãŸ
ãã¯äžèšåŒçšæç®äžã«ããåŒçšæç®ïŒã«ãããŠã»
ãã®èŠé ã®ããã«æèšããããããªæäžç¯å²ä»¥å
ïŒäžè¬ã«ã¯å°éåŽïŒã®éããã³æäžæ³ïŒé »åºŠãçµ
è·¯ããã³çµæç©ïŒã«åŸã€ãŠå®æœããã 奜é©ã§éœåè¯ãããšã«ããããã·ã«ã ããã³æ¬
çºæã®èåºæ¿ããã³æœ°çæå¶å€ã¯äžåã®äœµçšåŠæ¹
ã§æäžã§ãããããã¯éå£åŸæäžã«é©ããååŒã§
ãããããããçµå£æäžã«é©ããååŒã§ããã䜵
çšæäžåœ¢æ ã«ãããåè¬åã®å²åã¯åäžæäžãã
æã®åè¬åã®åæ¥æäžéã®æ¯çãšããã䜵çšè¬å
ã¯äžåãŸãã¯åå²æçšã§è¡ãªããæ¥äžåæäžã¯ç¬¬
äºã®å»è¬åã®çäœå åæžæãïŒãããã·ã ã®ãã
ã«ïŒæ¯èŒçé·ãå Žåããã³å žåçæ人æ£è çšã®ç¬¬
äºå»è¬åã®äžæ¥æäžéãïŒãïŒïœãããå°éãã
ãªæ¯èŒçå°ãªãå Žåã«æã奜é©ã§ããã 奜é©ãªçµå£æäžã§ã¯ãå¹³åçæ人æ£è çšã®ãã
ãã·ã«ã ïŒãŸãã¯ãã®å¡©ïŒéã¯å¯äœçšã«æåæ§ã®
é«ãæ£è ã«ãããŠãããã·ã«ã ã«ããèªçºããã
èè žåºæ¿ãŸãã¯æœ°çãæå¶ããã«äžè¬çã«å åãª
第äºã®å»è¬åã®éïŒäžèšåç §ïŒãšã®äœµçšã§ïŒã50
mgïŒæ¥ã®ç¯å²ãäžè¬çã§ããïŒ ã¢ã»ãã¢ããããšã³ 200ã4000mgïŒæ¥ïŒ ããã»ãã³ ïŒã200mgïŒæ¥ïŒ ãã«ããããŒã« ïŒã100mgïŒæ¥ïŒ ãžã¢ãŒãã ïŒã40mgïŒæ¥ïŒ ããªããŸã·ã³ ïŒã500mgïŒæ¥ïŒ ããªããã·ã³ ïŒã2000mgïŒæ¥ïŒã 䜵çšååç©ã¯åäžã§ãŸãã¯å»è¬ãšããŠé©åœãªæ
äœãŸãã¯åžéå€ãšã®äœµçšã§æäžããããçµå£äœ¿çš
ã®ããã«å¥œé©ãªå»è¬çšæ äœãšããŠã¯äžæŽ»æ§ãªåžé
å€ãŸãã¯å å¡«å€ãæããããé å€ãç²æ«ãã«ãã»
ã«ãªã©ã®ãããªæäžåœ¢æ ã圢æãããå¿ èŠãªã
ã°ããããã®å»è¬çµæç©ã¯éŠå³æãçµåå€ã賊圢
å€ãªã©ã®æ·»å æåãå«ããããšãã§ãããäŸãã°
ã¯ãšã³é žãããªãŠã ã®ãããªçš®ã ã®è³Šåœ¢å€ãå«æ
ããé å€ã¯æŸ±ç²ãã¢ã«ã®ã³é žããã³çªé žå¡©è€åäœ
ã®ãããªçš®ã ã®åŽ©å£å€ãšäŒŽã«ãŸãã¯ããªããã«ã
ããªãã³ãã·ãšç³ããŒã©ãã³ããã³ã¢ã©ãã¢ãŽã
ã®ãããªçµåå€ãšäŒŽã«äœ¿çšããããæŽã«ãã¹ãã¢
ãªã³é žãã°ãã·ãŠã ãã©ãŠãªã«ç¡«é žãããªãŠã ã
ãã³ã¿ã«ã¯ã®ãããªæœ€æ»å€ããã°ãã°é å€åã®ç®
çã«æçšã§ãããåæ§ã®ååŒã®åºäœçµæç©ãè»ã
ãã³ç¡¬å å¡«ãŒã©ãã³ã«ãã»ã«äžã®å å¡«å€ãšããŠäœ¿
çšãããããã®ããã®å¥œé©ãªç©è³ªãšããŠã¯ã©ã¯ã
ãŒã¹ãŸãã¯ä¹³ç³ããã³é«ååéããªãšãã¬ã³ã°ãª
ã³ãŒã«ãæããããã æ¬çºæã以äžã®å®æœäŸã«äŸèšŒãããããããæ¬
çºæã¯ãããã®å®æœäŸã®ç¹å®ã®çŽ°ç®ã«éå®ããã
ãã®ã§ã¯ãªããšç解ãã¹ãã§ããã å®æœäŸ å®æœäŸ ïŒ ã©ããã«ããããããã·ã«ã èªçºæ§èå·å®³ãžã®
çš®ã ã®å»è¬åã®ä¿è·å¹æ äœé140ã160ïœã®CD系統ãã¹ãã©ãŒã¯âããŠ
ãªãŒïŒSpraqueâDawleyïŒãã®æçéãç¹æ®ç¡
èâã©ããã¯ãã€ãŒã«ãºãªããŒããªãŒãã€ã³ã°ã©
ãã©ããªãŒãºïŒCharles River Breeding
LaboratoriesïŒïŒKingstonãN.Y.ïŒããå ¥æã
ããåç©ã¯çŽäžé±éé å¿ãããäœéã200ã225ïœ
ã«éããæã«è©Šéšãããã©ããã16æéæé£ã
ããå¹³åäœéã«é¢ããŠæšæºåããããã«ïŒã20é
ã®åç©ãããªã矀ã«ç¡äœçºåããã 0.1ïŒ ã¡ãã«ã»ã«ããŒã¹æ°Žæº¶æ¶²ïŒPHïŒ6.8ïŒïŒml
äžã®ãããã·ã«ã ãäžåã§100mgïŒKgæäžéã§çµ
å£æäžããããšã«ããåç©ã«è朰çãèªçºããã
ãã第äºã®å»è¬åãæäžããåç©ã«ãã»ãŒåæã«
åäžæº¶åªïŒmläžã®ãããã·ã«ã ãæŽã«æäžããã
6.5æéåŸãåç©ãé éšè±èŒã§æ®ºãã解åããã
èãå€ç§çã«åé€ããè倧åœã«æ²¿ã€ãŠè§£åããå·
æ°Žã§ãããã ãèã¯çŽç·ç¶ããã³æç¹ç¶å·å®³ã®äž¡
æ¹ã«ã€ããŠåºäœå¥ã«èšé²ãããå·å®³ã®å šäœæ°ãèš
é²çšã«äœ¿çšãããå矀ã®ã©ããããåŸãããè³æ
ãå šäœã®èã®å·å®³ã®å¹³åå€ïŒïŒâæšæºèª€å·®ãèšç®
ããåŸãåæãããåŸãããå€ãé察è³æçšã®äž¡
åŽã¹ããŠãŒãã³ãæ€å®ã«ãããããã·ã«ã ã®ã¿
ãæäžãããå¯Ÿç §ãšæ¯èŒããããããã·ã«ã èªçº
æ§æœ°çã«å¯Ÿãã第äºå»è¬åã®ä¿è·å¹æãè¡šã«ç€º
ãããããã®è³æã¯ãã«ããããŒã«ãã¢ã»ãã¢ã
ãããšã³ããã¢ãããŸãŒã«ãããã»ãã³ããã³ãž
ã¢ãŒãã ãããããå¥åº·ãªåºå®ã©ããã«ãããã
ããã·ã«ã èªçºæ§èå·å®³ãèããæžå°ãããããš
ã瀺ããŠããã
ã·ã«ã ãŸãã¯ãã®å»è¬ãšããŠé©åœãªå¡©ãçµåãã
çµæç©ã«é¢ãããæ¬æ现æžã«äœ¿çšãããå±åã¯ã°
ãªãã€ã¹ãïŒGriffithsïŒç·šéã®ãžUSANã¢ã³ã
ãžUSPãã€ã¯ã·ãšããªãŒãªããã©ãã°ãã€ã ã¹
ïŒthe USAN and the USP Dictonary of Drug
NamesïŒã1961ã1981ãU.S.Pharmacopeial
Convention Inc.RockvilleãMdã1984ããçšã
å ¬åŒã®USANåãšåž°å±ããŠäº€ä»ãããããŸãã¯
ã¶ã¡ã«ã¯ã€ã³ããã¯ã¹10ã¹ãšãã€ã·ãšã³ïŒthe
Merck Index 10th EditionïŒã«è¡šããããŠããã æççå€ã«ã¯äžè¬ã«ä»éããå¯äœçšãšããŠæœ°ç
ãå«ããèè žåºæ¿ãå€å°ã¯çãããå€ãã®å Žåã
ãã®ãããªæççæ²»çãå¿ èŠãšããåºäœã¯ããã®
ãããªå¯äœçšãžã®æåæ§ã®ãããã®å©çã®äº«åã
劚ããããŠãããäžã§å®çŸ©ãããå»è¬åãšããã
ã·ã«ã ãšã®æ¬çµåãã¯äžè¿°ã®èè žåºæ¿ãŸãã¯æœ°ç
ãé²æ¢ãããæ¹åããç®çã®æççæ²»çãå¯èœã«
ããã åŸæ¥ã®æè¡ ã¢ã»ãã¢ããããšã³ã¯ã¢ã¹ããªã³ã®æœ°çèªçºæ§
ãæžå°ããããã·ãŠã¬ãŒã¹ïŒSugersïŒãããžã€
ãŒãã«ãªããã¢ãŒãã·ãŒã¢ã³ããã¢ãŒãã³ããžãŒ
ïŒJ.Pharm.Phaymacol.ïŒ30ã84ïŒ1978ïŒïŒåæžã
31ã840ïŒ1979ïŒïŒããã³ã¢ããã³ã»ã¹ãªãããã¹
ã¿ã°ã©ã³ãžã³ã¢ã³ãã¹ãã³ãããµã³ãªãµãŒã
ïŒAdv.Prost.Thromb.Res.ïŒïŒã1547ïŒ1980ïŒããŸ
ãã¯é žæ§åã¢ã¹ããªã³ã®æœ°çèªçºæ§ãæžå°ããã
ãã³ã³ãã¬ãã¯ïŒKonturekïŒããã¬ããïŒGutïŒã
23ã536ïŒ1982ïŒããšä»¥åã«å ±åãããŠããããã
ããã€ã³ãã¡ã¿ã·ã³ã¯é žæ§åã¢ã¹ããªã³ãæäžã
ãæã«ã¯ã¢ã»ãã¢ããããšã³ã®ä¿è·äœçšãé転ã
ããïŒäžèšåŒçšæïŒãæè¿ã®ç 究ã§ã¯ãã¢ã»ãã¢
ããããšã³ã¯ã€ã³ãã¡ã¿ã·ã³ããã³ã¢ã¹ããªã³ã®
朰çèªçºæ§ãæžå°ãããããšãã«ãã¿ãŸã³ãŸãã¯
ã°ã©ããšãã³ããã³æé«æäžïŒ800mgïŒKgïŒæã®
ã€ãããããšã³ã®æœ°çèªçºæ§ã¯æžå°ãããªããšå ±
åãããããã¢ã³ã³ã«ãã·ãšãã³ïŒvan
KolfschotenïŒãããšã€ãžãšã³ãã¢ã¯ã·ãšã³ãº
ïŒAgents ActionsïŒ12ã247ïŒ1982ïŒïŒããã·ã³ã
ãžãŒã¢ã³ãã¢ãã©ã€ããã¢ãŒãã³ããžãŒ
ïŒToxicology Applied Pharm.ïŒ69ã37ïŒ1983ïŒãã
ã±ãããããšã³ããã³ä»ã®ç¹å®ã®æççå€ãšçµå
ããã¢ã»ãã¢ããããšã³ã¯åäžæ·»å æã®å¹æãã
ã倧ããªé®çå¹æãäŸçµŠãããšå ±åãããïŒç±³åœ
ç¹èš±ç¬¬4233313ã4233317å·ïŒ4234601å·ïŒ4207340
å·ããã³4242353å·ïŒããããã·ã«ã ãŸãã¯ä»ã®ã
ããªããªãã·ã«ã ãšã¢ã»ãã¢ããããšã³ãšã®äœµçš
ã«é¢ããŠã¯ããããªãç®ççšã«ã以åã«å ±åãã
ãŠã¯ããªãã æ°ç®¡æ¯æ¡åŒµå€ãµã«ãã¿ã¢ãŒã«ïŒã¢ã«ããããŒ
ã«ïŒããšãã«ãšããšããªã³ããã³ã€ãœãããã¬ã
ãŒã«ã¯åç©ã«ãããã€ã³ãã¡ã¿ã·ã³èªçºæ§æœ°çã®
圢æãæå¶ããããããã©ãããŒã«ã¯æå¶ããªã
ãšå ±åãããŠããããã€ãŒã«ãã€ã³ã°
ïŒFieldingïŒãããšãŒããã¢ã³ãµãŒãžã«ã«ãªãµãŒ
ãïŒEur Surg ResïŒïŒã252ïŒ1977ïŒïŒã«ã¹ã€
ïŒKasuyaïŒãããžã€ãããŒãºãžã€ãŒãã«ãªããã¢
ãŒãã³ããžãŒJapan J.Pharm.ïŒ29ã670ïŒ1979ïŒãã
ä»ã®ç 究ã§ã¯ãç¬ã®åºåºå®€éšäœãžã®ã€ãœãããã¬
ããŒã«æäžã¯ã¢ã¹ããªã³èªçºæ§çµç¹æå·ã軜æžãŸ
ãã¯é²æ¢ããããããã¯ã°ãªãŒããŒïŒMcGreevyïŒ
ãããµãŒãžã«ã«ããªãŒã©ã ïŒSurg.ForumïŒ28ã
357ïŒ1977ïŒããæ°ç®¡æ¯æ¡åŒµå€ãã«ããããŒã«ã®æç
çå€ãžã®åœ±é¿ã«é¢ããå ±åã¯ãŸã ç¥ãããŠããª
ãã æãã€å€ããã»ãã³ãèã®åæ³æå¶æŽ»æ§ããæ
ãã人éã®åäºæè žæœ°çæ²»çã«ãããŠã·ã¡ããžã³
ãšåæ§ã«æå¹ã§ãããšå ±åãããŠãããããã
ïŒHoffïŒããã«ã¬ã³ãã¡ãã€ã«ã«ãªãµãŒãã¢ã³ã
ãªãããªã³ïŒCurr Med Res OpinïŒç¬¬ïŒå·»ãå¢
åïŒã36ããŒãžïŒ1980ïŒïŒã¹ã«ã³ãžããã¢ã³ãžã€
ãŒãã«ãªãã¬ã¹ãããšã³ããããžãŒïŒScand.J.
Gastroent.ïŒã16ã1041ïŒ1981ïŒããããã»ãã³ãã©
ããããã³ç¬ã«ãããŠæœ°çæå¶ããã³åæ³æå¶æŽ»
æ§ã瀺ãã氎浞ææã«ããã¹ãã¬ã¹ããããã©ã
ãã«ãããŠã€ã³ãã¡ã¿ã·ã³ããžã¯ãããšããã¯ã
ãã³ã¢ã¹ããªã³ã®æœ°çèªçºåãèããæžå°ããã
ããšãå ±åãããŠãããã¬ã€ããŒã«ãïŒLeitoldïŒ
ããã¢ãŒã«ã€ãã¹ãªããã¢ãŒãã³ããžãŒïŒArch.
Pharmacol.ïŒ316ïŒå¢åïŒãR50ãèŠçŽ199
ïŒ1981ïŒïŒã¬ã€ããŒã«ãïŒLeitoldïŒããã¢ããã³
ã»ã¹ã€ã³ãšã¯ã¹ããªã¡ã³ã¿ã«ãŠã«ãµãŒ
ïŒAdvances in Experimental UlcerïŒããŠãšãã©
ããã³ã€ããŠç·šéãICEU.Tokyo.pp27ã36
ïŒ1982ïŒïŒã¢ã«ããã€ãããã«âããªã«ã·ãŠã³ã°ïŒ
ãã©ãã¯ãªãµãŒãïŒArzneim.âForsch.ïŒDrug
Res.ïŒã34ã468ïŒ1984ïŒãã ã¡ãžã€ãŒãã©ã³ãã©ã€ã¶ãŒã§æ粟ç¥ç å€ã§ãã
ã¯ãã«ããããžã³ã¯ã©ããã®ã€ã³ãã¡ã¿ã·ã³èªçº
æ§è朰çã軜æžãããšå ±åãããŠãããã«ã¹ã€
ïŒKasuyaïŒããäžèšåŒçšæïŒ1979ïŒããæè¿ãå ç«
調æŽå€ã¬ãããœãŒã«ãã©ããã®ãããã·ã«ã ãã
ã³ã€ã³ãã¡ã¿ã·ã³èªçºæ§æœ°çã®äž¡è ãšã軜æžãã
ãšå ±åãããŠããããšãã³ã²ãªã¹ã¿
ïŒEvangelistaïŒãããžã€ãŒãã«ãªããã¢ãŒãã·ãŒ
ã¢ã³ããã¢ãŒãã³ããžãŒïŒJ.Pharm.Pharmacol.ïŒ
36ã270ïŒ1984ïŒããããããéã¹ããã€ãç³»æçç
å€ã«ããèªçºãããèãžã®å¯äœçšã®è»œæžã«ããªã
ãŸã·ã³ã®ãããªæé«è¡å§å€ãããªããã·ã³ã®ãã
ãªãã¿ãã³ãŸãã¯ãžã¢ãŒãã ã®ãããªãã€ããŒã
ã©ã³ãã©ã€ã¶ãŒã®äœ¿çšã«é¢ããå ±åã¯ããŸã ã«ç¥
ãããŠããªãã ãªã³è質ãéã¹ããã€ãç³»æççå€ãç¹ã«ã€ã
ããããšã³ãããããã»ã³ããžã¯ãããšããã¯ã
ãã³ãã«ãªãããããšã³ã®ããšãã«é ¢é žããã³ã
ãšãã«ããããªã³é žèªå°äœãã®ã¯ãžãŒïŒGkyczyïŒ
ããç±³åœç¹èš±ç¬¬4369182å·ïŒ1983ïŒãã以åã€ã³ã
ã¡ã¿ã·ã³ããã³ä»ã®æççå€ãšäœµçšããã朰çæ
å¶å€ãã¬ã³ãŒãã³ãã¬ã€ããŒã«ãïŒLeitoldïŒãã
ãã©ãã€ããã·ãšïŒTherapiewocheïŒã27ã
pp1532ã1548ïŒ1977ïŒïŒãã€ãç¹èš±ç¬¬2708520å·ã
ããã³ã©ãããžã³ãã·ã¡ããžã³ããã³ïŒâã¡ãã«
âïŒâããïŒâïŒïŒâãããªãžãã«ã¡ãã«ïŒããšã
ãã·ãâãããã«ã¢ããããâ1HâïŒïŒïŒïŒïŒâã
ãªã¢ãŸãŒã«âïŒâã¡ã¿ããŒã«ã®ãããªãã¹ããžã³
âH2æ®ææ§ïŒèé žåæ³æå¶ã朰çæå¶ïŒååç©ã
ãšäœµçšããå Žåã«èè žã®èŠçïŒç²èãžã®æå·ãè
朰ç圢æïŒã軜æžãããšå ±åãããŠãããäŸã
ã°ãè±åœç¹èš±ç¬¬2105193ããã³2105588å·ïŒããã³
ã©ãã¬ã€ã¹ïŒLavelaceïŒãç±³åœç¹èš±ç¬¬4230717å·
ãåç §ããã ãã³ãã«ãžãïŒLombardinoïŒã«ããåæåºé¡
ãããç±³åœç¹èš±ç¬¬4567179å·ã¯ããªããŸã·ã³ãã
ãã»ãã³ãâãžã¡ãã«ããã»ãã³ãããªããã·
ã³ãã€ãœãããã¬ããŒã«ããã³ãã«ããããŒã«ã
å«ãããããã·ã«ã ã®æ¹è¯ãããæççæ§å¡©ã«ã€
ããŠèšè¿°ããŠããã çºæã解決ããããšããåé¡ç¹ æ¬çºæã¯æççéã®ãããã·ã«ã ãŸãã¯ãã®å»
è¬ãšããŠé©åœãªå¡©ïŒç¹ã«ãšã¿ããŒã«ã¢ãã³å¡©ïŒã
ãããã·ã«ã èªçºæ§èåºæ¿éããã³æœ°çæå¶éã®
ã¢ã»ãã¢ããããšã³ãããã»ãã³ããã«ããããŒ
ã«ããžã¢ãŒãã ãããªããŸã·ã³é¡ãããªããã·ã³
é¡ããã³ãããã®å»è¬ãšããŠé©åœãªå¡©ãšäœµçšãã
ããšãç¹é·ãšããæçççµæç©ã®æ¹è¯ã«é¢ããã åé¡ã解決ããããã®æ段 æ¬çºæã®æççããããã·ã«ã ã¯æ¢ç¥ç©è³ªã§ã
ããäŸãã°ãã¶ã¡ã«ã¯ã€ã³ããã¯ã¹ïŒthe Merck
IndexïŒç¬¬10çã1983ã«ã¯ãããã·ã«ã ã«é¢ãã
éçŽïŒNo.7378ïŒãå«ãŸããŠãããã¶ãã€ãžã·ã¢ã³
ãºãã¹ã¯ãªãã¢ã¬ã³ã¹ãThe Physicians Desk
ReferenceïŒPDRïŒãã«ãå«ãŸããŠããã奜é©ãªã
ããã·ã«ã ã®ãšã¿ããŒã«ã¢ãã³å¡©ã¯ç±³åœç¹èš±ç¬¬
4434164å·ã«æ確ã«é瀺ãããŠããã æã ããããã·ã«ã èªçºæ§èåºæ¿ããã³æœ°çã
æå¶ããããšãèŠåºããæ¬çºæã®ååç©ãæ¢ç¥å
åç©ã§ãããã¢ã»ãã¢ããããšã³ã¯å°å£²ã®é®çå€
ãã¶ã¡ã«ã¯ã€ã³ããã¯ã¹ïŒthe Merck IndexïŒç¬¬
10çãéæçªå·39ïŒPDR第38çãp.2096ãåç §ã
ã§ãããããã»ãã³ã¯ãã®å¡©é žå¡©ã®åœ¢ç¶ã§è²©å£²ã
ããŠããæãã€å€ã§ãããã¶ã¡ã«ã¯ã€ã³ããã¯ã¹
ïŒthe Merck IndexïŒç¬¬10çãéçŽçªå·3434ïŒ
PDR第38çãpp.1688ã1689ïŒãããã«ããããŒã«
ã¯ãã®äºå¡©é žäžé ¢é žå¡©ã®åœ¢ç¶ã§äžçäžã«è²©å£²ãã
ãŠããæ°ç®¡æ¯æ¡åŒµå€ã§ãããã¶ã¡ã«ã¯ã€ã³ããã¯
ã¹ïŒthe Merck IndexïŒç¬¬10çãéçŽçªå·7364
ãåç §ãããæ°ç®¡æ¯æ¡åŒµå€ãšããŠã®åæã®åæã
ãã³å¹çšã¯ç±³åœç¹èš±ç¬¬3700681ïŒ3763173ïŒ
3772314ããã³3786160å·ã«é瀺ãããŠãããã»ã
ã«äžè¬çã«æ¹è¯ãããåæãç±³åœç¹èš±3948919ïŒ
4011231ïŒããã³4031108å·ïŒã«ã¯ã»ã³ãã«ã°ç¹èš±
第79564å·ããã³ãšãŒãããç¹èš±ç³è«ç¬¬58069ã
58070ã58071ããã³58072å·ã«ç€ºãããŠãããæŽ
ã«æè¿ããã«ããããŒã«ã¯æ¬è¡æ§å¿äžå šã®æ²»çã«
ãæå¹ã§ããããšãå€æããïŒç±³åœç¹èš±ç¬¬
4175128å·ïŒããžã¢ãŒãã ã¯åºãåŠæ¹ãããŠããã
ã€ããŒãã©ã³ãã©ã€ã¶ãŒã§ãããã¶ã¡ã«ã¯ã€ã³ã
ãã¯ïŒthe Merck IndexïŒç¬¬10çãéçŽçªå·
2967ïŒPDR第39çãpp.1671ã1674ããããªã¢ãŸ
ã·ã³ãã¶ã¡ã«ã¯ã€ã³ããã¯ã¹ïŒthe Merck
IndexïŒç¬¬10çãéçŽçªå·9506ïŒãã¯å¡©é žå¡©ãšã
ãŠäžçäžã«è²©å£²ãããŠããæ§é äžãã©ãŸã·ã³ã«é¢
é£ããæè¡å§å€ã§ãããããªããã·ã³ã¯B6è€å
äœã®ãã¿ãã³ã®äžã€ãšããŠå¡©é žå¡©ãšããŠè²©å£²ãã
ãŠããã ãããã·ã«ã èªçºæ§èåºæ¿ããã³æœ°çã®æå¶ã«
ãããæ¬çºæã®æ¹è¯åŠæ¹ã®èšåºç䟡å€ã¯é©åœãªå
ç©å®éšã«åæ ãããããããã·ã«ã èªçºæ§èå·å®³
ãé²æ¢ãŸãã¯è»œæžããããã®è©Šéšååç©ã®èœåã
決å®ãã代衚çãªå®éšèšé²ãäžèšã®å®æœäŸã«ç€º
ãã æ¬çºæã¯å®¹æã«å®æœã§ããããããã·ã«ã ãŸã
ã¯ãã®å¡©ãåç©ãç¹ã«äººéã«0.1ãïŒmgïŒKgïŒæ¥
ã®ç¯å²ã§æäžããã第äºã®å»è¬åãå¥ã ã«æäžã
ãå Žåã«ã¯ãå è¡æè¡ïŒäŸãã°äžèšã®åŒçšæç®ãŸ
ãã¯äžèšåŒçšæç®äžã«ããåŒçšæç®ïŒã«ãããŠã»
ãã®èŠé ã®ããã«æèšããããããªæäžç¯å²ä»¥å
ïŒäžè¬ã«ã¯å°éåŽïŒã®éããã³æäžæ³ïŒé »åºŠãçµ
è·¯ããã³çµæç©ïŒã«åŸã€ãŠå®æœããã 奜é©ã§éœåè¯ãããšã«ããããã·ã«ã ããã³æ¬
çºæã®èåºæ¿ããã³æœ°çæå¶å€ã¯äžåã®äœµçšåŠæ¹
ã§æäžã§ãããããã¯éå£åŸæäžã«é©ããååŒã§
ãããããããçµå£æäžã«é©ããååŒã§ããã䜵
çšæäžåœ¢æ ã«ãããåè¬åã®å²åã¯åäžæäžãã
æã®åè¬åã®åæ¥æäžéã®æ¯çãšããã䜵çšè¬å
ã¯äžåãŸãã¯åå²æçšã§è¡ãªããæ¥äžåæäžã¯ç¬¬
äºã®å»è¬åã®çäœå åæžæãïŒãããã·ã ã®ãã
ã«ïŒæ¯èŒçé·ãå Žåããã³å žåçæ人æ£è çšã®ç¬¬
äºå»è¬åã®äžæ¥æäžéãïŒãïŒïœãããå°éãã
ãªæ¯èŒçå°ãªãå Žåã«æã奜é©ã§ããã 奜é©ãªçµå£æäžã§ã¯ãå¹³åçæ人æ£è çšã®ãã
ãã·ã«ã ïŒãŸãã¯ãã®å¡©ïŒéã¯å¯äœçšã«æåæ§ã®
é«ãæ£è ã«ãããŠãããã·ã«ã ã«ããèªçºããã
èè žåºæ¿ãŸãã¯æœ°çãæå¶ããã«äžè¬çã«å åãª
第äºã®å»è¬åã®éïŒäžèšåç §ïŒãšã®äœµçšã§ïŒã50
mgïŒæ¥ã®ç¯å²ãäžè¬çã§ããïŒ ã¢ã»ãã¢ããããšã³ 200ã4000mgïŒæ¥ïŒ ããã»ãã³ ïŒã200mgïŒæ¥ïŒ ãã«ããããŒã« ïŒã100mgïŒæ¥ïŒ ãžã¢ãŒãã ïŒã40mgïŒæ¥ïŒ ããªããŸã·ã³ ïŒã500mgïŒæ¥ïŒ ããªããã·ã³ ïŒã2000mgïŒæ¥ïŒã 䜵çšååç©ã¯åäžã§ãŸãã¯å»è¬ãšããŠé©åœãªæ
äœãŸãã¯åžéå€ãšã®äœµçšã§æäžããããçµå£äœ¿çš
ã®ããã«å¥œé©ãªå»è¬çšæ äœãšããŠã¯äžæŽ»æ§ãªåžé
å€ãŸãã¯å å¡«å€ãæããããé å€ãç²æ«ãã«ãã»
ã«ãªã©ã®ãããªæäžåœ¢æ ã圢æãããå¿ èŠãªã
ã°ããããã®å»è¬çµæç©ã¯éŠå³æãçµåå€ã賊圢
å€ãªã©ã®æ·»å æåãå«ããããšãã§ãããäŸãã°
ã¯ãšã³é žãããªãŠã ã®ãããªçš®ã ã®è³Šåœ¢å€ãå«æ
ããé å€ã¯æŸ±ç²ãã¢ã«ã®ã³é žããã³çªé žå¡©è€åäœ
ã®ãããªçš®ã ã®åŽ©å£å€ãšäŒŽã«ãŸãã¯ããªããã«ã
ããªãã³ãã·ãšç³ããŒã©ãã³ããã³ã¢ã©ãã¢ãŽã
ã®ãããªçµåå€ãšäŒŽã«äœ¿çšããããæŽã«ãã¹ãã¢
ãªã³é žãã°ãã·ãŠã ãã©ãŠãªã«ç¡«é žãããªãŠã ã
ãã³ã¿ã«ã¯ã®ãããªæœ€æ»å€ããã°ãã°é å€åã®ç®
çã«æçšã§ãããåæ§ã®ååŒã®åºäœçµæç©ãè»ã
ãã³ç¡¬å å¡«ãŒã©ãã³ã«ãã»ã«äžã®å å¡«å€ãšããŠäœ¿
çšãããããã®ããã®å¥œé©ãªç©è³ªãšããŠã¯ã©ã¯ã
ãŒã¹ãŸãã¯ä¹³ç³ããã³é«ååéããªãšãã¬ã³ã°ãª
ã³ãŒã«ãæããããã æ¬çºæã以äžã®å®æœäŸã«äŸèšŒãããããããæ¬
çºæã¯ãããã®å®æœäŸã®ç¹å®ã®çŽ°ç®ã«éå®ããã
ãã®ã§ã¯ãªããšç解ãã¹ãã§ããã å®æœäŸ å®æœäŸ ïŒ ã©ããã«ããããããã·ã«ã èªçºæ§èå·å®³ãžã®
çš®ã ã®å»è¬åã®ä¿è·å¹æ äœé140ã160ïœã®CD系統ãã¹ãã©ãŒã¯âããŠ
ãªãŒïŒSpraqueâDawleyïŒãã®æçéãç¹æ®ç¡
èâã©ããã¯ãã€ãŒã«ãºãªããŒããªãŒãã€ã³ã°ã©
ãã©ããªãŒãºïŒCharles River Breeding
LaboratoriesïŒïŒKingstonãN.Y.ïŒããå ¥æã
ããåç©ã¯çŽäžé±éé å¿ãããäœéã200ã225ïœ
ã«éããæã«è©Šéšãããã©ããã16æéæé£ã
ããå¹³åäœéã«é¢ããŠæšæºåããããã«ïŒã20é
ã®åç©ãããªã矀ã«ç¡äœçºåããã 0.1ïŒ ã¡ãã«ã»ã«ããŒã¹æ°Žæº¶æ¶²ïŒPHïŒ6.8ïŒïŒml
äžã®ãããã·ã«ã ãäžåã§100mgïŒKgæäžéã§çµ
å£æäžããããšã«ããåç©ã«è朰çãèªçºããã
ãã第äºã®å»è¬åãæäžããåç©ã«ãã»ãŒåæã«
åäžæº¶åªïŒmläžã®ãããã·ã«ã ãæŽã«æäžããã
6.5æéåŸãåç©ãé éšè±èŒã§æ®ºãã解åããã
èãå€ç§çã«åé€ããè倧åœã«æ²¿ã€ãŠè§£åããå·
æ°Žã§ãããã ãèã¯çŽç·ç¶ããã³æç¹ç¶å·å®³ã®äž¡
æ¹ã«ã€ããŠåºäœå¥ã«èšé²ãããå·å®³ã®å šäœæ°ãèš
é²çšã«äœ¿çšãããå矀ã®ã©ããããåŸãããè³æ
ãå šäœã®èã®å·å®³ã®å¹³åå€ïŒïŒâæšæºèª€å·®ãèšç®
ããåŸãåæãããåŸãããå€ãé察è³æçšã®äž¡
åŽã¹ããŠãŒãã³ãæ€å®ã«ãããããã·ã«ã ã®ã¿
ãæäžãããå¯Ÿç §ãšæ¯èŒããããããã·ã«ã èªçº
æ§æœ°çã«å¯Ÿãã第äºå»è¬åã®ä¿è·å¹æãè¡šã«ç€º
ãããããã®è³æã¯ãã«ããããŒã«ãã¢ã»ãã¢ã
ãããšã³ããã¢ãããŸãŒã«ãããã»ãã³ããã³ãž
ã¢ãŒãã ãããããå¥åº·ãªåºå®ã©ããã«ãããã
ããã·ã«ã èªçºæ§èå·å®³ãèããæžå°ãããããš
ã瀺ããŠããã
ãè¡šã
å®æœäŸ ïŒ
ãããã·ã«ã ã®ãšã¿ããŒã«ã¢ãã³å¡©ã«ããèªçº
ãããã©ããã®èå·å®³ãžã®çš®ã ã®å»è¬åã®ä¿è·
å¹æ åã®å®æœäŸã«åŸãããããã·ã«ã ã®ãšã¿ããŒã«
ã¢ãã³å¡©ã®100ã200mgïŒKgã®äžåæäžã«ãããè
朰çãèªçºãããããè©ŠéšçŸ€ã«ã¯è¡šã«ç€ºããã
ãªçš®ã ã®å»è¬åãçš®ã ã®æäžéã§äžãããããã
ã®è³æã¯è©Šéšååç©ãå¥åº·ãªæé£ã©ããã«ããã
ãããã·ã«ã ã®ãšã¿ããŒã«ã¢ãã³å¡©ã«ããèªçºã
ããèå·å®³ãèããæžå°ãããããšã瀺ããŠã
ãã
ãããã©ããã®èå·å®³ãžã®çš®ã ã®å»è¬åã®ä¿è·
å¹æ åã®å®æœäŸã«åŸãããããã·ã«ã ã®ãšã¿ããŒã«
ã¢ãã³å¡©ã®100ã200mgïŒKgã®äžåæäžã«ãããè
朰çãèªçºãããããè©ŠéšçŸ€ã«ã¯è¡šã«ç€ºããã
ãªçš®ã ã®å»è¬åãçš®ã ã®æäžéã§äžãããããã
ã®è³æã¯è©Šéšååç©ãå¥åº·ãªæé£ã©ããã«ããã
ãããã·ã«ã ã®ãšã¿ããŒã«ã¢ãã³å¡©ã«ããèªçºã
ããèå·å®³ãèããæžå°ãããããšã瀺ããŠã
ãã
ãè¡šã
å®æœäŸ ïŒ
ã©ããã®ãããã·ã«ã èªçºæ§èå·å®³ãžã®ã¢ã»ã
ã¢ããããšã³ã®ä¿è·å¹æ å¹³åäœé190ïœã®éã©ãããã¹ãã©ãŒã¯âããŠ
ãªãŒïŒSpraqueâDawleyïŒããæ¬ç 究ã«çšããã
åç©ãäžæ©æé£ããã次ãã§0.1ïŒ ã¡ãã«ã»ã«ã
ãŒã¹äžã«æžæ¿ããè©Šéšååç©ãæäžãããããã
ã·ã«ã ãŸãã¯ãã®äœµçšç©ã®æäžåŸ6.5æéã§ã©ã
ããæäžããé ã«æ®ºãããèãååºããæ°Žéæ°Žã§
ããããïŒæã®å¡©æ°Žã浞ããã¿ãªã«ã®éã«äžæ©ä¿
管ãããç¿æèã調ã¹æœ°çã®æ°ãæ±ãããåå·å®³
ã«ã€ããŠæ°å€ã¯å€§ãããšåŒ·åºŠã§æå®ããããïŒçš®
ã®æ°å€ã®çµæã匷床å åãšåŒã³ã匷床å åã®åèš
ã¯ãã®èã®æœ°çã®ç¹æ°ãè¡šããããïŒã€ã®å¥ã ã®
å®éšïŒïŒã€ã¯ç²æ€ïŒãå®æœããè¡šã«å«ãŸããè³
æãåŸããè³æã¯ã¢ã»ãã¢ããããšã³ãå¥åº·ãªã©
ããã«ãããŠ32mgïŒKgã®ãããã·ã«ã ã®å·å®³å¹æ
ãèãããã®ä¿è·ã¯æäžéã«äŸåããããšã瀺ã
ãŠããã ãããã·ã«ã ã32mgïŒKgã§çµå£æäžãããã®ãš
ã¢ã»ãã¢ããããšã³ã250mgïŒKgã§çµå£ãŸãã¯ç®
äžæäžãããã®ãšã®å¥ã ã®ç 究ã¯ã¢ã»ãã¢ããã
ãšã³ããããã·ã«ã ã®è¡æŒ¿ã¬ãã«ã«åœ±é¿ããªãã
ãšã瀺ãã ãããã·ã«ã ïŒ32mgïŒKgçµå£ïŒæäžåã®16ãã
ã³ïŒæéåã«ã¢ã»ãã¢ããããšã³ïŒ250mgïŒKgçµ
å£ïŒããããããæäžããã©ããã¯ãã®æ¹æ³ã«ã
ããããã·ã«ã ã§èªçºãããèè žå·å®³ããã¯ãã
ã»ã©ä¿è·ãããªãã€ãã
ã¢ããããšã³ã®ä¿è·å¹æ å¹³åäœé190ïœã®éã©ãããã¹ãã©ãŒã¯âããŠ
ãªãŒïŒSpraqueâDawleyïŒããæ¬ç 究ã«çšããã
åç©ãäžæ©æé£ããã次ãã§0.1ïŒ ã¡ãã«ã»ã«ã
ãŒã¹äžã«æžæ¿ããè©Šéšååç©ãæäžãããããã
ã·ã«ã ãŸãã¯ãã®äœµçšç©ã®æäžåŸ6.5æéã§ã©ã
ããæäžããé ã«æ®ºãããèãååºããæ°Žéæ°Žã§
ããããïŒæã®å¡©æ°Žã浞ããã¿ãªã«ã®éã«äžæ©ä¿
管ãããç¿æèã調ã¹æœ°çã®æ°ãæ±ãããåå·å®³
ã«ã€ããŠæ°å€ã¯å€§ãããšåŒ·åºŠã§æå®ããããïŒçš®
ã®æ°å€ã®çµæã匷床å åãšåŒã³ã匷床å åã®åèš
ã¯ãã®èã®æœ°çã®ç¹æ°ãè¡šããããïŒã€ã®å¥ã ã®
å®éšïŒïŒã€ã¯ç²æ€ïŒãå®æœããè¡šã«å«ãŸããè³
æãåŸããè³æã¯ã¢ã»ãã¢ããããšã³ãå¥åº·ãªã©
ããã«ãããŠ32mgïŒKgã®ãããã·ã«ã ã®å·å®³å¹æ
ãèãããã®ä¿è·ã¯æäžéã«äŸåããããšã瀺ã
ãŠããã ãããã·ã«ã ã32mgïŒKgã§çµå£æäžãããã®ãš
ã¢ã»ãã¢ããããšã³ã250mgïŒKgã§çµå£ãŸãã¯ç®
äžæäžãããã®ãšã®å¥ã ã®ç 究ã¯ã¢ã»ãã¢ããã
ãšã³ããããã·ã«ã ã®è¡æŒ¿ã¬ãã«ã«åœ±é¿ããªãã
ãšã瀺ãã ãããã·ã«ã ïŒ32mgïŒKgçµå£ïŒæäžåã®16ãã
ã³ïŒæéåã«ã¢ã»ãã¢ããããšã³ïŒ250mgïŒKgçµ
å£ïŒããããããæäžããã©ããã¯ãã®æ¹æ³ã«ã
ããããã·ã«ã ã§èªçºãããèè žå·å®³ããã¯ãã
ã»ã©ä¿è·ãããªãã€ãã
ãè¡šã
ãè¡šã
å®æœäŸ ïŒ
ãããã·ã«ã ãšã¿ããŒã«ã¢ãã³å¡©ã«ããèªçºã
ããã©ããã®èå·å®³ãžã®ããã»ãã³ããã³ã¢ã»
ãã¢ããããšã³ã®äºé²ããã³æ²»çå¹æ å®æœäŸïŒããã³ïŒã®æ¹æ³ã«åŸã€ãŠãããã»ãã³
ãŸãã¯ã¢ã»ãã¢ããããšã³ãäºé²çïŒæ®ºãåïŒã
24æéïŒã«ãŸãã¯æ²»ççïŒæ®ºãåïŒãïŒæéïŒã«
æäžãã100mgïŒKgã®ãããã·ã«ã ãšã¿ããŒã«ã¢
ãã³å¡©æäžåŸ6.5æéã§ã©ããã殺ãããçµæã
è¡šã«ç€ºããããã®æäœæ³ã®ããšãã¢ã»ãã¢ãã
ããšã³ã¯ãããã·ã«ã ã®æäžã®1.5æéåã«æäž
ãããšäžè²«ããŠä¿è·æŽ»æ§ã瀺ããã
ããã©ããã®èå·å®³ãžã®ããã»ãã³ããã³ã¢ã»
ãã¢ããããšã³ã®äºé²ããã³æ²»çå¹æ å®æœäŸïŒããã³ïŒã®æ¹æ³ã«åŸã€ãŠãããã»ãã³
ãŸãã¯ã¢ã»ãã¢ããããšã³ãäºé²çïŒæ®ºãåïŒã
24æéïŒã«ãŸãã¯æ²»ççïŒæ®ºãåïŒãïŒæéïŒã«
æäžãã100mgïŒKgã®ãããã·ã«ã ãšã¿ããŒã«ã¢
ãã³å¡©æäžåŸ6.5æéã§ã©ããã殺ãããçµæã
è¡šã«ç€ºããããã®æäœæ³ã®ããšãã¢ã»ãã¢ãã
ããšã³ã¯ãããã·ã«ã ã®æäžã®1.5æéåã«æäž
ãããšäžè²«ããŠä¿è·æŽ»æ§ã瀺ããã
ãè¡šã
ã ã®ãšã¿ããŒã«ã¢ãã³å¡©ãäžããã
å®æœäŸ ïŒ ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ã¢ã»ã
ã¢ããããšã³ïŒ1000mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ïŒç²æ«åïŒã¢ã»ãã¢ããããšã³ 1000 çé žã«ã«ã·ãŠã 250 ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒå¹³åååéã4000ïŒ
430 æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åããã
1200mgã®æ··åç©ãé©åœãªãµã€ãºã®ã«ãã»ã«ã«å å¡«
ããããã·ã«ã ïŒ20mgïŒããã³ã¢ã»ãã¢ããããš
ã³ïŒ1000mgïŒãå«ãã è»ãŒã©ãã³ã«ãã»ã«ã補é
ããã 硬ãŒã©ãã³å å¡«ã«ãã»ã«ãäœãã«ã¯ãç®çéã®
å掻æ§æåãå«ãã æšæºçãµã€ãºã®ãŒã©ãã³ã«ã
ã»ã«ãéœåããæºããããã«äžæŽ»æ§æåã®éã調
æŽããã å®æœäŸ ïŒ ã«ãã»ã«âãããã·ã«ã ïŒ10mgïŒããã³ã¢ã»ã
ã¢ããããšã³ïŒ500mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã ãšã¿ããŒã«ã¢ãã³å¡©
11.84ïŒéé¢é žãšããŠ10ã«çžåœïŒ ïŒç²æ«åïŒã¢ã»ãã¢ããããšã³ 500 ã³ãŒã³ã¹ã¿ãŒã 485.16 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ãé©åœãªãµã€ãºã®ç¡¬ãŒã©ãã³ã«ãã»
ã«ã«å å¡«ããç®çã®å¹åã®å掻æ§æåãå«ãã ã«
ãã»ã«ã補é ããïŒå å¡«éé1000mgïŒã å®æœäŸ ïŒ ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ããã»
ãã³ïŒ15mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ããã»ãã³å¡©é žå¡©16ïŒéé¢å¡©åºãšããŠ15ã«çžåœïŒ ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒå¹³åååé4000ïŒ 664 æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ïŒå å¡«éé700mgïŒãé©åœãªãµã€ãº
ã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ããç®çã®å¹åã®ã«
ãã»ã«ã補é ããã å®æœäŸ ïŒ ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ããã»
ãã³ïŒ50mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ïŒç²æ«åïŒããã»ãã³å¡©é žå¡©
533ïŒéé¢å¡©åºãšããŠ50ã«çžåœïŒ ã³ãŒã³ã¹ã¿ãŒã 633.7 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããµã€
ãºïŒã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ãïŒå å¡«éé
700mgïŒãç®çã®å¹åã®åæåãå«ãã ã«ãã»ã«ã
補é ããã å®æœäŸ ïŒ é å€âãããã·ã«ã ïŒ20mgïŒããã³ããã»ãã³
ïŒ20mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ïŒç²æ«åïŒããã»ãã³å¡©é žå¡©
21.3ïŒéé¢å¡©åºãšããŠ20ã«çžåœïŒ ä¹³ ç³ 186.7 ããããã·ãããã«ã¡ãã«ã»ã«ããŒã¹ ïŒ ã¹ã¿ãŒãã°ãªã³ãŒã«é žãããªãŠã 15 ã¹ãã¢ãªã³é žãã°ãã·ã ãŠ ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åããã
250mgã®ééã«çžåœãã容ç©ã®ç²æ«ããç®çã®å¹
åã®å掻æ§æåãå«ãã é å€ã«æé ããã å®æœäŸ 10 é å€âãããã·ã«ã ïŒ20mgïŒããã³ãã«ããã
ãŒã«ïŒ25mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã ãšã¿ããŒã«ã¢ãã³
23.68ïŒéé¢å¡©åºãšããŠ20ã«çžåœïŒ ãã«ããããŒã«ã¢ã»ãã€ã
31.28ïŒéé¢å¡©åºãšããŠ25ã«çžåœïŒ ä¹³ ç³ 220.04 ããããã·ãããã«ã¡ãã«ã»ã«ããŒã¹ ïŒ ã¹ã¿ãŒãã°ãªã³ãŒã«é žãããªãŠã 16 ã»ãã¢ãªã³é žãã°ãã·ã ãŠ ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åããã
300mgã®ééã«çžåœãã容ç©ã®ç²æ«ããç®çã®å¹
åã®å掻æ§æåãå«ãã é å€ã«æé ããã å®æœäŸ 11 ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ãã«ã
ãããŒã«ïŒ20mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ïŒç²æ«åïŒããããããŒã«ãå¡©é žå¡©
26.1ïŒéé¢å¡©åºãšããŠ20ã«çžåœïŒ ã³ãŒã³ã¹ã¿ãŒã 652.9 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ïŒå å¡«éé700mgïŒãé©åœãªãµã€ãº
ã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ããç®çã®å¹åã®ã«
ãã»ã«ã補é ããã ãããã·ã«ã ãšã¿ããŒã«ã¢ãã³å¡©ïŒ23.7ïŒãšã
ã«ããããŒã«ã¢ãã¢ã»ãã€ãïŒ23.4ïŒãšã®çéç©
ãã³ãŒã³ã¹ã¿ãŒãããã³ã¹ãã¢ãªã³é žãã°ãã·ãŠ
ã ãšäœµçšããåæ§ã®æ¹æ³ã§ç¡¬ãŒã©ãã³ã«ãã»ã«ã«
å å¡«ãããšãå掻æ§æåãå«ãåæ§ã®å¹åã®ã«ã
ã»ã«ãåŸãããã å®æœäŸ 12 ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ãžã¢ãŒ
ãã ïŒ10mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã ãšã¿ããŒã«ã¢ãã³å¡©
23.68ïŒéé¢é žãšããŠ20ã«çžåœïŒ ãžã¢ãŒãã 10 çé žã«ã«ã·ãŠã 50 ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒå¹³åååé4000ïŒ
166.32 æ··åç©ãåäžç²æ«ã«æ··åããé©åœãªãµã€ãºã®ç¡¬
ãŒã©ãã³ã«ãã»ã«ã«å å¡«ãïŒå å¡«éé250mgïŒãç®
çã®å¹åã®ã«ãã»ã«ã補é ããã å®æœäŸ 13 é å€âãããã·ã«ã ïŒ10mgïŒããã³ãžã¢ãŒãã
ïŒïŒmgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã 10 ãžã¢ãŒãã ïŒ ä¹³ ç³ 123 ããããã·ãããã«ã¡ãã«ã»ã«ããŒã¹ ïŒ ã¹ã¿ãŒãã°ãªã³ãŒã«é žãããªãŠã ïŒ ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åããã
150mgã®ééã«çžåœãã容ç©ã®ç²æ«ããç®çã®å¹
åã®å掻æ§æåãå«ãã é å€ã«æé ããã å®æœäŸ 14 ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ããªã
ãŸã·ã³ïŒ40mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã 20 ããªããŸã·ã³å¡©é žå¡©âæ°Žåç©
45ïŒéé¢å¡©åºãšããŠ40ã«çžåœïŒ ã³ãŒã³ã¹ã¿ãŒã 362 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ïŒå å¡«éé700mgïŒãé©åœãªãµã€ãº
ã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ããç®çã®å¹åã®å
è¬åãå«ãã ã«ãã»ã«ã補é ããã å®æœäŸ 15 ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ããªã
ãã·ã³ïŒ20mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã 20 ããªããã·ã³å¡©é žå¡©
24.3ïŒéé¢å¡©åºãšããŠ20ã«çžåœïŒ ã³ãŒã³ã¹ã¿ãŒã 652.7 ã¹ãã¢ãªã³é žãã°ãã·ã ãŠ ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ïŒå å¡«éé700mgïŒãé©åœãªå€§ãã
ã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ããç®çã®å¹åã®å
è¬åãå«ãã ã«ãã»ã«ã補é ããã å®æœäŸ 16 é å€âãããã·ã«ã ïŒ10mgïŒããã³ããªããã·
ã³ïŒ10mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã 10 ããªããã·ã³å¡©é žå¡©
12.15ïŒéé¢å¡©åºãšããŠ10ã«çžåœïŒ ä¹³ ç³ 253.85 ããããã·ãããã«ã¡ãã« ã»ã«ããŒã¹ ïŒ ã¹ã¿ãŒãã°ãªã³ãŒã«é žãããªãŠã 15 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«æ··åãã300mgã®ééã«çž
åœãã容ç©ãæé ããç®çã®å¹åã®åè¬åãå«ã
ã é å€ã補é ããã
å®æœäŸ ïŒ ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ã¢ã»ã
ã¢ããããšã³ïŒ1000mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ïŒç²æ«åïŒã¢ã»ãã¢ããããšã³ 1000 çé žã«ã«ã·ãŠã 250 ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒå¹³åååéã4000ïŒ
430 æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åããã
1200mgã®æ··åç©ãé©åœãªãµã€ãºã®ã«ãã»ã«ã«å å¡«
ããããã·ã«ã ïŒ20mgïŒããã³ã¢ã»ãã¢ããããš
ã³ïŒ1000mgïŒãå«ãã è»ãŒã©ãã³ã«ãã»ã«ã補é
ããã 硬ãŒã©ãã³å å¡«ã«ãã»ã«ãäœãã«ã¯ãç®çéã®
å掻æ§æåãå«ãã æšæºçãµã€ãºã®ãŒã©ãã³ã«ã
ã»ã«ãéœåããæºããããã«äžæŽ»æ§æåã®éã調
æŽããã å®æœäŸ ïŒ ã«ãã»ã«âãããã·ã«ã ïŒ10mgïŒããã³ã¢ã»ã
ã¢ããããšã³ïŒ500mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã ãšã¿ããŒã«ã¢ãã³å¡©
11.84ïŒéé¢é žãšããŠ10ã«çžåœïŒ ïŒç²æ«åïŒã¢ã»ãã¢ããããšã³ 500 ã³ãŒã³ã¹ã¿ãŒã 485.16 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ãé©åœãªãµã€ãºã®ç¡¬ãŒã©ãã³ã«ãã»
ã«ã«å å¡«ããç®çã®å¹åã®å掻æ§æåãå«ãã ã«
ãã»ã«ã補é ããïŒå å¡«éé1000mgïŒã å®æœäŸ ïŒ ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ããã»
ãã³ïŒ15mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ããã»ãã³å¡©é žå¡©16ïŒéé¢å¡©åºãšããŠ15ã«çžåœïŒ ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒå¹³åååé4000ïŒ 664 æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ïŒå å¡«éé700mgïŒãé©åœãªãµã€ãº
ã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ããç®çã®å¹åã®ã«
ãã»ã«ã補é ããã å®æœäŸ ïŒ ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ããã»
ãã³ïŒ50mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ïŒç²æ«åïŒããã»ãã³å¡©é žå¡©
533ïŒéé¢å¡©åºãšããŠ50ã«çžåœïŒ ã³ãŒã³ã¹ã¿ãŒã 633.7 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããµã€
ãºïŒã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ãïŒå å¡«éé
700mgïŒãç®çã®å¹åã®åæåãå«ãã ã«ãã»ã«ã
補é ããã å®æœäŸ ïŒ é å€âãããã·ã«ã ïŒ20mgïŒããã³ããã»ãã³
ïŒ20mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ïŒç²æ«åïŒããã»ãã³å¡©é žå¡©
21.3ïŒéé¢å¡©åºãšããŠ20ã«çžåœïŒ ä¹³ ç³ 186.7 ããããã·ãããã«ã¡ãã«ã»ã«ããŒã¹ ïŒ ã¹ã¿ãŒãã°ãªã³ãŒã«é žãããªãŠã 15 ã¹ãã¢ãªã³é žãã°ãã·ã ãŠ ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åããã
250mgã®ééã«çžåœãã容ç©ã®ç²æ«ããç®çã®å¹
åã®å掻æ§æåãå«ãã é å€ã«æé ããã å®æœäŸ 10 é å€âãããã·ã«ã ïŒ20mgïŒããã³ãã«ããã
ãŒã«ïŒ25mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã ãšã¿ããŒã«ã¢ãã³
23.68ïŒéé¢å¡©åºãšããŠ20ã«çžåœïŒ ãã«ããããŒã«ã¢ã»ãã€ã
31.28ïŒéé¢å¡©åºãšããŠ25ã«çžåœïŒ ä¹³ ç³ 220.04 ããããã·ãããã«ã¡ãã«ã»ã«ããŒã¹ ïŒ ã¹ã¿ãŒãã°ãªã³ãŒã«é žãããªãŠã 16 ã»ãã¢ãªã³é žãã°ãã·ã ãŠ ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åããã
300mgã®ééã«çžåœãã容ç©ã®ç²æ«ããç®çã®å¹
åã®å掻æ§æåãå«ãã é å€ã«æé ããã å®æœäŸ 11 ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ãã«ã
ãããŒã«ïŒ20mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ïŒç²æ«åïŒãããã·ã«ã 20 ïŒç²æ«åïŒããããããŒã«ãå¡©é žå¡©
26.1ïŒéé¢å¡©åºãšããŠ20ã«çžåœïŒ ã³ãŒã³ã¹ã¿ãŒã 652.9 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ïŒå å¡«éé700mgïŒãé©åœãªãµã€ãº
ã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ããç®çã®å¹åã®ã«
ãã»ã«ã補é ããã ãããã·ã«ã ãšã¿ããŒã«ã¢ãã³å¡©ïŒ23.7ïŒãšã
ã«ããããŒã«ã¢ãã¢ã»ãã€ãïŒ23.4ïŒãšã®çéç©
ãã³ãŒã³ã¹ã¿ãŒãããã³ã¹ãã¢ãªã³é žãã°ãã·ãŠ
ã ãšäœµçšããåæ§ã®æ¹æ³ã§ç¡¬ãŒã©ãã³ã«ãã»ã«ã«
å å¡«ãããšãå掻æ§æåãå«ãåæ§ã®å¹åã®ã«ã
ã»ã«ãåŸãããã å®æœäŸ 12 ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ãžã¢ãŒ
ãã ïŒ10mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã ãšã¿ããŒã«ã¢ãã³å¡©
23.68ïŒéé¢é žãšããŠ20ã«çžåœïŒ ãžã¢ãŒãã 10 çé žã«ã«ã·ãŠã 50 ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒå¹³åååé4000ïŒ
166.32 æ··åç©ãåäžç²æ«ã«æ··åããé©åœãªãµã€ãºã®ç¡¬
ãŒã©ãã³ã«ãã»ã«ã«å å¡«ãïŒå å¡«éé250mgïŒãç®
çã®å¹åã®ã«ãã»ã«ã補é ããã å®æœäŸ 13 é å€âãããã·ã«ã ïŒ10mgïŒããã³ãžã¢ãŒãã
ïŒïŒmgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã 10 ãžã¢ãŒãã ïŒ ä¹³ ç³ 123 ããããã·ãããã«ã¡ãã«ã»ã«ããŒã¹ ïŒ ã¹ã¿ãŒãã°ãªã³ãŒã«é žãããªãŠã ïŒ ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åããã
150mgã®ééã«çžåœãã容ç©ã®ç²æ«ããç®çã®å¹
åã®å掻æ§æåãå«ãã é å€ã«æé ããã å®æœäŸ 14 ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ããªã
ãŸã·ã³ïŒ40mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã 20 ããªããŸã·ã³å¡©é žå¡©âæ°Žåç©
45ïŒéé¢å¡©åºãšããŠ40ã«çžåœïŒ ã³ãŒã³ã¹ã¿ãŒã 362 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ïŒå å¡«éé700mgïŒãé©åœãªãµã€ãº
ã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ããç®çã®å¹åã®å
è¬åãå«ãã ã«ãã»ã«ã補é ããã å®æœäŸ 15 ã«ãã»ã«âãããã·ã«ã ïŒ20mgïŒããã³ããªã
ãã·ã³ïŒ20mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã 20 ããªããã·ã³å¡©é žå¡©
24.3ïŒéé¢å¡©åºãšããŠ20ã«çžåœïŒ ã³ãŒã³ã¹ã¿ãŒã 652.7 ã¹ãã¢ãªã³é žãã°ãã·ã ãŠ ïŒ æ··åç©ãåäžç²æ«ã«ãªããŸã§ããæ··åãããç
æããæ··åç©ïŒå å¡«éé700mgïŒãé©åœãªå€§ãã
ã®ç¡¬ãŒã©ãã³ã«ãã»ã«ã«å å¡«ããç®çã®å¹åã®å
è¬åãå«ãã ã«ãã»ã«ã補é ããã å®æœäŸ 16 é å€âãããã·ã«ã ïŒ10mgïŒããã³ããªããã·
ã³ïŒ10mgïŒ äžèšæåãäžèšã®ééæ¯ã§äœµçšããïŒ ãããã·ã«ã 10 ããªããã·ã³å¡©é žå¡©
12.15ïŒéé¢å¡©åºãšããŠ10ã«çžåœïŒ ä¹³ ç³ 253.85 ããããã·ãããã«ã¡ãã« ã»ã«ããŒã¹ ïŒ ã¹ã¿ãŒãã°ãªã³ãŒã«é žãããªãŠã 15 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ æ··åç©ãåäžç²æ«ã«æ··åãã300mgã®ééã«çž
åœãã容ç©ãæé ããç®çã®å¹åã®åè¬åãå«ã
ã é å€ã補é ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ (a) æççéã®ãããã·ã«ã ãŸãã¯ãã®å»è¬
ãšããŠé©åœãªå¡©ïŒããã³ (b) èåºæ¿æå¶ããã³æœ°çæå¶éã®ããã»ãã³ãŸ
ãã¯ãã®å»è¬ãšããŠé©åœãªå¡©ãããªãæ¹è¯ãã
ãæçççµæç©ã ïŒ ããã»ãã³ããã®å¡©é žå¡©åã§ããããã·ã«ã
ããã®éé¢ã®ãšããŒã«åã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé èšèŒã®çµæç©ã ïŒ (a) æççéã®ãããã·ã«ã ãŸãã¯ãã®å»è¬
ãšããŠé©åœãªå¡©ïŒããã³ (b) èåºæ¿æå¶ããã³æœ°çæå¶éã®ãã«ããããŒ
ã«ãŸãã¯ãã®å»è¬ãšããŠé©åœãªå¡©ãããªãæ¹è¯
ãããæçççµæç©ã ïŒ ãã«ããããŒã«ããã®äºå¡©é žå¡©åã§ãããã
ã·ã«ã ããã®éé¢ã®ãšããŒã«åã§ããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé ã®çµæç©ã ïŒ ãã«ããããŒã«ããã®äžé ¢é žå¡©åããããã·
ã«ã ããã®ãšã¿ããŒã«ã¢ãã³å¡©åã§ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ (a) æççéã®ãããã·ã«ã ãŸãã¯ãã®å»è¬
ãšããŠé©åœãªå¡©ïŒããã³ (b) èåºæ¿æå¶ããã³æœ°çæå¶éã®ãžã¢ãŒãã ã
ããªãæ¹è¯ãããæçççµæç©ã ïŒ ãããã·ã«ã ããã®éé¢ã®ãšããŒã«åã§ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ ãããã·ã«ã ããã®ãšã¿ããŒã«ã¢ãã³å¡©åã§
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ (a) æççéã®ãããã·ã«ã ãŸãã¯ãã®å»è¬
ãšããŠé©åœãªå¡©ïŒããã³ (b) èåºæ¿æå¶ããã³æœ°çæå¶éã®ããªããŸã·ã³
ãŸãã¯ãã®å»è¬ãšããŠé©åœãªå¡©ãããªãæ¹è¯ã
ããæçççµæç©ã ïŒïŒ ããªããŸã·ã³ããã®å¡©é žå¡©åã§ããããã·
ã«ã ããã®éé¢ã®ãšããŒã«åã§ããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒïŒ (a) æççéã®ãããã·ã«ã ãŸãã¯ãã®å»
è¬ãšããŠé©åœãªå¡©ïŒããã³ (b) èåºæ¿æå¶ããã³æœ°çæå¶éã®ããªããã·ã³
ãŸãã¯ãã®å»è¬ãšããŠé©åœãªå¡©ãããªãæ¹è¯ã
ããæçççµæç©ã ïŒïŒ ãããã·ã«ã ããã®éé¢é žåã§ãããªãã
ã·ã³ããã®å¡©é žå¡©åã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒ
é èšèŒã®çµæç©ã ïŒïŒ (a) æççéã®ãããã·ã«ã ãŸãã¯ãã®å»
è¬ãšããŠé©åœãªå¡©ïŒããã³ (b) èåºæ¿æå¶ããã³æœ°çæå¶éã®ã¢ã»ãã¢ãã
ããšã³ãŸãã¯ãã®å»è¬ãšããŠé©åœãªå¡©ãããªã
æ¹è¯ãããæçççµæç©ã ïŒïŒ ã¢ã»ãã¢ããããšã³ããã®éé¢ããšããŒã«
åã§ããããã·ã«ã ããã®éé¢ã®ãšããŒã«åã§ã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®çµæç©ã
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65960284A | 1984-10-11 | 1984-10-11 | |
| US659602 | 1984-10-11 | ||
| US695590 | 1985-01-28 | ||
| US695518 | 1985-01-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6191124A JPS6191124A (ja) | 1986-05-09 |
| JPH0428245B2 true JPH0428245B2 (ja) | 1992-05-13 |
Family
ID=24646022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60226665A Granted JPS6191124A (ja) | 1984-10-11 | 1985-10-11 | æçççµæç© |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US4579846A (ja) |
| JP (1) | JPS6191124A (ja) |
| DD (1) | DD238920A5 (ja) |
| HU (1) | HU195110B (ja) |
| ZA (1) | ZA857784B (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR890001236B1 (ko) * | 1985-10-02 | 1989-04-28 | íìŽì ìžìœí¬ë ìŽí°ë | ììŒì ì¡°ì±ë¬Œì ì ì¡°ë°©ë² |
| US4965065A (en) * | 1986-04-29 | 1990-10-23 | Bristol-Myers Squibb Company | Gastroprotective process and compositions |
| US5260333A (en) * | 1986-08-08 | 1993-11-09 | Bristol Myers Squibb Company | Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions |
| IT1241088B (it) * | 1990-03-27 | 1993-12-29 | Chiesi Farma Spa | Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche |
| IT1262953B (it) * | 1992-03-12 | 1996-07-23 | Depalmo Galli | Composizione a base di ibuprofen per uso orale. |
| US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
| GB9820746D0 (en) * | 1998-09-23 | 1998-11-18 | Pharmax Limited | Micronised pharmaceutical compositions |
| AU2002312967A1 (en) * | 2001-06-19 | 2003-01-02 | Norbert Muller | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders |
| US20050176809A1 (en) * | 2004-02-05 | 2005-08-11 | Rodlen Laboratories, Inc. | Method and compositions for treatment of painful disorders |
| DOP2007000055A (es) * | 2006-04-10 | 2007-10-31 | Senosiain S A De C V Lab | Composición farmaceutica que comprende un analgésico y vitaminas |
| MX2008003230A (es) * | 2008-03-07 | 2009-09-07 | Senosiain S A De C V Lab | Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b. |
| US20130109655A1 (en) * | 2011-10-31 | 2013-05-02 | Serghei Gargaun | Method for mitigating of Prostaglandin E2 reducing side effects of non-steroidal anti-inflammatory drugs |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1083044A (en) * | 1976-05-04 | 1980-08-05 | Stewart Wong | Antiarthritic potentiation |
| US4233316A (en) * | 1978-12-18 | 1980-11-11 | Mcneilab, Inc. | Analgesic potentiation |
| US4233317A (en) * | 1978-12-18 | 1980-11-11 | Mcneilab, Inc. | Analgesic potentiation |
| US4207340A (en) * | 1978-12-18 | 1980-06-10 | Mcneilab, Inc. | Analgesic potentiation |
| US4233315A (en) * | 1978-12-18 | 1980-11-11 | Mcneilab, Inc. | Analgesic potentiation |
| US4234601A (en) * | 1978-12-18 | 1980-11-18 | Mcneilab, Inc. | Analgesic potentiation |
| US4233314A (en) * | 1978-12-18 | 1980-11-11 | Mcneilab, Inc. | Analgesic potentiation |
| US4242353A (en) * | 1978-12-18 | 1980-12-30 | Mcneilab, Inc. | Analgesic potentiation |
| US4233313A (en) * | 1978-12-18 | 1980-11-11 | Mcneilab, Inc. | Analgesic potentiation |
| EP0109281A1 (en) * | 1982-11-15 | 1984-05-23 | The Upjohn Company | Compositions comprising flurbiprofen or ibuprofen |
-
1985
- 1985-01-28 US US06/695,590 patent/US4579846A/en not_active Expired - Lifetime
- 1985-01-28 US US06/695,518 patent/US4564614A/en not_active Expired - Fee Related
- 1985-10-09 ZA ZA857784A patent/ZA857784B/xx unknown
- 1985-10-10 HU HU853941A patent/HU195110B/hu not_active IP Right Cessation
- 1985-10-10 DD DD85281624A patent/DD238920A5/de not_active IP Right Cessation
- 1985-10-11 JP JP60226665A patent/JPS6191124A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| US4579846A (en) | 1986-04-01 |
| ZA857784B (en) | 1987-05-27 |
| HU195110B (en) | 1988-04-28 |
| JPS6191124A (ja) | 1986-05-09 |
| US4564614A (en) | 1986-01-14 |
| HUT38540A (en) | 1986-06-30 |
| DD238920A5 (de) | 1986-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4446140A (en) | Method and composition for treating mouth pain | |
| US5037815A (en) | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers | |
| EP0320551A1 (en) | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2 receptor blockers | |
| EP0550083B1 (en) | Medicaments for treating inflammatory conditions or for analgesia containing a NSAID and ranitidine bismuth citrate | |
| JPH06502854A (ja) | è幎çŽåãéé£çãçé çãŸãã¯é£æ¬²äžæ¯ã®æ²»ççšã®ãããã»ãã³ã®äœ¿çš | |
| US4766117A (en) | Antiinflammatory compositions and methods | |
| JPH0428245B2 (ja) | ||
| JP3018160B2 (ja) | æçµå°é£çåã³ïŒåã¯æçµåçå矀ã®è»œæžçšè¬å€ | |
| EP0190851B1 (en) | Improved antiinflammatory composition | |
| JPH0140009B2 (ja) | ||
| US4874757A (en) | Antinflammatory compositions and methods | |
| AU666992B2 (en) | Pharmaceutical composition for preventing or treating arteriosclerosis | |
| EP0218453B1 (en) | Improved antiinflammatory compositions and methods | |
| EP0178122B1 (en) | Improved piroxicam-containing antiinflammatory compositions | |
| CA1228817A (en) | Analgesic preparations | |
| JP3982889B2 (ja) | ã€ããããã§ã³å«æå»è¬è£œå€ | |
| US4812455A (en) | Antiinflammatory compositions and methods | |
| US4036957A (en) | Phenoxy compounds in combinations to suppress gastric bleeding in aspirin therapy | |
| EP2682109B1 (en) | Combined immediate release formulations of flurbiprofen and famotidine | |
| GB2135884A (en) | Analgesic preparations containing tizanidine and paracetamol | |
| IE43955B1 (en) | Pharmaceutical composition and dosage units thereof | |
| AU690664B2 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion | |
| KR970006083B1 (ko) | ìì¥ì§í ì¹ë£ì© ììœ ì¡°ì±ë¬Œ | |
| JPS6360926A (ja) | æåè¬ | |
| JPS5839623A (ja) | ãã©ãŸãã³ãå¿ é æåãšããæ朰çå€ |